DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018 - 2026)
DiaMedica Therapeutics (DMAC) reported Gains from Investment Securities of $6.4 million for Q1 2026, up 213403.2% on a YoY basis from N/an in Q1 2025, and up 12.22% quarter-over-quarter from $5.7 million in Q3 2025.
DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics has reported Gains from Investment Securities for 9 years, with the latest figure at $6.4 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 213403.2% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (up 79963.7% YoY), and the FY2025 full-year result was $6.9 million, up 46.3% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $6.4 million, up from $5.7 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $6.7 million in Q2 2025, with the low at $1000.0 in Q4 2022.
- Historically, Gains from Investment Securities has averaged $2.3 million across 5 years, with a median of $989398.0 in 2022.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities tumbled 83.33% — and 2026, when it surged 213403.2%.
- DiaMedica Therapeutics' Gains from Investment Securities stood at $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then surged by 200.0% to $3000.0 in 2024, then soared by 190148.13% to $5.7 million in 2025, then grew by 12.22% to $6.4 million in 2026.
- The last three Gains from Investment Securities figures came in at $6.4 million (Q1 2026), $5.7 million (Q3 2025), and $6.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | DiaMedica Therapeutics | 285.11 Mn | 233.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.41 Mn |
| Mar 31, 2026 | 6.41 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Sep 30, 2025 | 5.71 Mn |
| Jun 30, 2025 | 6.69 Mn |
| Jun 30, 2025 | 6.69 Mn |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 4.63 Mn |
| Sep 30, 2024 | 4.63 Mn |
| Jun 30, 2024 | 4.86 Mn |
| Jun 30, 2024 | 4.86 Mn |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 450,410.00 |
| Sep 30, 2023 | 450,410.00 |